Clinical trial
Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients…
NCT00247975 · Ottawa Heart Institute Research Corporation, Other · Terminated
Key facts
| NCT number | NCT00247975 |
|---|---|
| Title | Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy |
| Official title | Primary Prevention of Anthracycline-Induced Cardiotoxicity With L-Carnitine in Patients With Breast Cancer (PPACC)-Pilot Study |
| Lead sponsor | Ottawa Heart Institute Research Corporation, Other |
| Collaborators | Canadian Institutes of Health Research (CIHR) |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Heart Failure |
| Intervention type | Drug |
| Interventions | L-carnitine |
| Enrollment | 36 |
| Start date | Mar 1, 2006 |
| Primary completion | Oct 1, 2010 |
| Completion | Oct 1, 2011 |
| First posted | Nov 2, 2005 |
| Last update posted | Aug 16, 2022 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: